The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Li, Jing ^a   Davies, Barry R ^a   Han, Sufang ^a   Zhou, Minhua ^a   Bai, Yu ^a   Zhang, Jingchuan ^a   Xu, Yan ^a   Tang, Lily ^a   Wang, Huiying ^a   Liu, Yuan J ^a   Yin, Xiaolu ^a   Ji, Qunsheng ^a   Yu, De Hua ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 5363; DOCETAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GENE MUTATION; GENETIC LINKAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MONOTHERAPY; MUTATION; NONHUMAN; PROTEIN DEPLETION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STOMACH CANCER; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CELL LINE, TUMOR; CELL PROLIFERATION; CHINA; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MUTATION; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; PYRROLES; STOMACH NEOPLASMS; TAXOIDS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884741607     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-241     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Canc J Clin 2005, 55:74-108.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Canc J Clin 2011, 61:69-90.
3. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730. 10.1056/NEJMoa010187, 11547741.
4. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010, 17:CD004064.
5. Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?. Oncologist 2012, 17:346-358. 10.1634/theoncologist.2011-0311, 3316920, 22334453.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. 10.1016/S0140-6736(10)61121-X, 20728210.
7. Bellacosa A, Kumar CC, Di Cristofano A, et al. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Canc Res 2005, 94:29-86.
8. Murayama T, Inokuchi M, Takagi Y, et al. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Canc 2009, 100:782-788.
9. Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastrica cancer and serves as a target for therapy in an experimental model. Int J Canc 2007, 120:1803-1810.
10. Yu G, Wang J, Chen Y, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Canc Res 2009, 15:1821-1829.
11. Byun DS, Cho K, Ryu BK, et al. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Canc 2003, 104:318-327.
12. Li VS, Wong CW, Chan TL, et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Canc 2005, 5:29.
13. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002, 82:285-291. 10.1038/labinvest.3780422, 11896207.
14. Im SA, Lee KE, Nam E, et al. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005, 91:513-521.
15. Oki E, Baba H, Tokunaga E, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Canc 2005, 117:376-380.
16. Oki E, Kakeji Y, Tokunaga E, et al. Impact of PTEN/AKT/PI3K signal pathway on the chemotherapy for gastric cancer. J Clin Oncol 2006, 24(18):4034. Meeting Abstracts.
17. Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Canc Ther 2012, 11:873-887.
18. Simon R, Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 2002, 30:1365-1372. 10.1016/S0301-472X(02)00965-7, 12482497.
19. Dunlap J, Le C, Shukla A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Canc Res Treat 2010, 120:409-418.
20. Li YL, Tian Z, Wu DY, et al. Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol 2005, 11:285-288.
21. Cervantes A, Roda D, Tarazona N, et al. Current questions for the treatment of advanced gastric cancer. Canc Treat Rev 2013, 39:60-67.
22. Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res 2011, 31:4387-4392.
23. Yoon DH, Ryu MH, Park YS, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Canc 2012, 106:1039-1044.
24. Georgescu MM. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Canc 2010, 1:1170-1177.
25. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012, 181:401-412. 10.1016/j.ajpath.2012.04.026, 22705054.
26. Lin J, Sampath D, Nannini MA, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Canc Res 2013, 19:1760-1772.
27. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Canc 2005, 41:1649-1654.
28. Barbi S, Cataldo I, De Manzoni G, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Canc Res 2010, 29:32.
29. Shi J, Yao D, Liu W, et al. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Canc 2012, 12:50.
30. Broet P, Dalmasso C, Tan EH, et al. Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Canc Res 2011, 17:3542-3550.
31. Udai B, Malcolm R, Jan HS, et al. Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors 2013, 104th AACR Annual meeting, Abstract no: LB-66.